Renner E L
Institut für Klinische Pharmakologie, Universität Bern.
Schweiz Med Wochenschr. 1994 Mar 26;124(12):495-501.
Several subtypes of autoimmune chronic active hepatitis can be distinguished today, one variant of which seems to be associated with active hepatitis C virus infection. Except for the latter, all types respond well to immunosuppressive therapy with prednisone (+/- azathioprine). Therapy has been shown to prolong survival, but the disease nevertheless often progresses to cirrhosis. For conservative therapy of primary biliary cirrhosis, D-penicillamine is contraindicated and several immunosuppressants investigated are associated with unacceptable side effects; ursodeoxycholic acid, colchicine and perhaps methotrexate seem to be promising, but none has been proven to prolong survival. Therefore, patients with primary biliary cirrhosis should still be included in therapeutic trials. In the advanced stages of both diseases liver transplantation remains an effective therapy.
如今可区分出几种自身免疫性慢性活动性肝炎的亚型,其中一种变异型似乎与丙型肝炎病毒的活动性感染有关。除了后者,所有类型对泼尼松(±硫唑嘌呤)的免疫抑制治疗反应良好。治疗已被证明可延长生存期,但疾病仍常常进展为肝硬化。对于原发性胆汁性肝硬化的保守治疗,D-青霉胺是禁忌的,所研究的几种免疫抑制剂都有不可接受的副作用;熊去氧胆酸、秋水仙碱以及或许甲氨蝶呤似乎有前景,但尚无一种被证明可延长生存期。因此,原发性胆汁性肝硬化患者仍应纳入治疗试验。在这两种疾病的晚期,肝移植仍然是一种有效的治疗方法。